New drug cocktail aims to wipe out Triple-Positive breast tumors before surgery
NCT ID NCT07299890
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a combination of four drugs (trastuzumab, pertuzumab, palbociclib, and exemestane) given before surgery to 90 people with early-stage triple-positive breast cancer. The goal is to see if this treatment can completely eliminate cancer cells in the breast and lymph nodes. Participants will receive the drugs for a set period before surgery, and researchers will monitor how well the tumors respond and any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?